Plant Name: Typha orientalis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; DRD4; | |
| NPSR1; CXCR1; | |
| RECQL; TDP1; PLA2G1B; CDA; CTDSP1; TK1; ADK; PIK3R1; GLO1; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALOX12; NOX4; PYGL; POLB; | |
| AKT1; MET; CAMK2B; CSNK2A1; DAPK1; NEK2; FLT3; NEK6; PKN1; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; PIM1; NUAK1; ALK; AXL; KDR; | |
| CA12; CA9; CA3; CA14; CA7; CA5A; CA1; CA4; CA6; CA2; | |
| AR; | |
| ESRRA; | |
| KDM4E; | |
| MAOA; ALOX5; TYR; XDH; | |
| MMP13; MMP3; MMP2; MMP9; | |
| BACE1; | |
| AHR; STAT6; HIF1A; NFKB1; TP53; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| ABCC1; ABCG2; | |
| LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.306E-13 | 4.465E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.556E-12 | 1.382E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.211E-12 | 5.768E-09 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.453E-11 | 8.554E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.967E-10 | 8.921E-08 | ABCC1, ABCG2, ADK, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TK1, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.863E-10 | 1.426E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.021E-10 | 1.436E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.133E-10 | 2.353E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.351E-09 | 4.263E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.378E-09 | 9.679E-07 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, CDA, ESRRA, GLO1, MMP13, MMP2, MMP3, MMP9, TK1, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.990E-09 | 1.572E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.328E-07 | 2.389E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.936E-07 | 3.427E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.708E-07 | 4.755E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 6.968E-07 | 1.018E-04 | ABCG2, ADORA2A, AKT1, ALK, CAMK2B, CDA, CSNK2A1, DAPK1, DRD4, FLT3, IGF1R, KDR, MET, MMP9, NFKB1, PYGL, SMN1, SMN2, STAT6, TK1, TP53, TYR, XDH |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 8.606E-07 | 1.217E-04 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.077E-07 | 1.267E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.486E-06 | 1.985E-04 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.809E-06 | 2.331E-04 | CYP1A1, CYP2C8, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 3.156E-06 | 3.655E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.856E-06 | 5.313E-04 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1, PLA2G1B, SRC |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 7.525E-06 | 7.840E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 8.515E-06 | 8.705E-04 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 8.912E-06 | 8.996E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 8.924E-06 | 8.996E-04 | ADORA2A, AURKB, CA2, CA7, HIF1A, NEK2, NPSR1, PLA2G1B |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.030E-05 | 1.020E-03 | ADORA1, ADORA2A, AURKB, CA2, CA7, HIF1A, KDR, NEK2, NPSR1, PLA2G1B, SRC |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.047E-05 | 1.027E-03 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.312E-05 | 1.258E-03 | AHR, CSNK2A1, HIF1A, KDR |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 1.648E-05 | 1.553E-03 | AKT1, MET, NEK2, PIK3R1, STAT6, TP53 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.925E-05 | 1.792E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 2.052E-05 | 1.846E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.052E-05 | 1.846E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.060E-05 | 1.846E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 2.052E-05 | 1.846E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.052E-05 | 1.846E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 2.052E-05 | 1.846E-03 | SLC28A2, SLC28A3 |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 2.201E-05 | 1.948E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.528E-05 | 2.160E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 2.528E-05 | 2.160E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 2.850E-05 | 2.396E-03 | ADORA1, ADORA2A, ADORA3, AKT1, ALOX15, AXL, CXCR1, NFKB1, NOX4, POLB |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 3.355E-05 | 2.746E-03 | ADK, AHR, AKR1B1, AKT1, ALOX12, ALOX15, ALOX5, AR, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDA, CDK1, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, LMNA, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PYGL, SMN1, SMN2, SRC, STAT6, TK1, TP53, TYR, XDH |
| BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 4.426E-05 | 3.479E-03 | ADORA2A, AKT1, AR, CDK1, CSNK2A1, DRD4, GSK3B, HIF1A, LMNA, NPSR1, PIK3R1, PLA2G1B, SRC, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.559E-05 | 3.571E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.902E-05 | 3.785E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 5.195E-05 | 3.969E-03 | AKT1, LMNA, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 5.933E-05 | 4.379E-03 | CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 5.933E-05 | 4.379E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 6.138E-05 | 4.396E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.138E-05 | 4.396E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 6.138E-05 | 4.396E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.138E-05 | 4.396E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 6.138E-05 | 4.396E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 6.138E-05 | 4.396E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 6.138E-05 | 4.396E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 6.176E-05 | 4.410E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.852E-05 | 4.844E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 1.078E-04 | 7.203E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.078E-04 | 7.203E-03 | AKT1, AR, DAPK1, LMNA, SRC |
| BP | GO:0050896; response to stimulus | GO:0048585; negative regulation of response to stimulus | 1.122E-04 | 7.447E-03 | ADORA1, ADORA2A, AKT1, ALOX12, ALOX15, AR, CYP19A1, DAPK1, GSK3B, HIF1A, IGF1R, LMNA, MET, MMP9, NFKB1, SRC, STAT6, XDH |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.129E-04 | 7.471E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.145E-04 | 7.511E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.152E-04 | 7.532E-03 | FLT3, HIF1A, KDR, PKN1, POLB, TYR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.224E-04 | 7.932E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.349E-04 | 8.690E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.515E-04 | 9.617E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.694E-21 | 7.288E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.971E-15 | 1.203E-11 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.729E-14 | 7.355E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.041E-20 | 5.474E-18 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 9.022E-11 | 5.413E-09 | CAMK2B; SRC; MMP2; KDR; AKT1; PIK3R1; TP53; HIF1A; MMP9; MET; PTK2; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.991E-09 | 7.724E-08 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; AKT1; MET; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.612E-11 | 3.251E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.146E-09 | 7.724E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.301E-08 | 2.926E-07 | CDA; PLA2G1B; MAOA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; CYP2C9; CYP2C8; HSD17B1; ALOX5; HSD17B2; CYP1A2; CYP1A1; TK1; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.012E-08 | 2.603E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.278E-09 | 1.883E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.289E-07 | 2.109E-06 | GSK3B; AR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 9.836E-08 | 1.771E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.290E-08 | 1.458E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.913E-07 | 7.369E-06 | FLT3; AKT1; PIK3R1; TP53; MET; HIF1A |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.245E-07 | 8.030E-06 | CYP2C9; CYP2C8; MAOA; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.529E-06 | 2.529E-05 | GSK3B; KDR; AKT1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.860E-07 | 8.030E-06 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 9.968E-07 | 1.121E-05 | ABCC1; ADORA3; ADORA1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 3.035E-06 | 2.875E-05 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.317E-06 | 2.454E-05 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.705E-06 | 3.335E-05 | SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.724E-07 | 1.121E-05 | DAPK1; SRC; MMP2; MMP9; TP53 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.203E-06 | 5.075E-05 | CAMK2B; AKT1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 5.141E-06 | 4.406E-05 | FLT3; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 7.204E-06 | 5.638E-05 | SRC; KDR; AKT1; PIK3R1; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.865E-06 | 7.103E-05 | CAMK2B; AKT1; PIK3R1; TP53; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.356E-05 | 9.389E-05 | GSK3B; SRC; AKT1; PIK3R1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.493E-05 | 9.792E-05 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.872E-05 | 1.087E-04 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.072E-05 | 1.626E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.865E-06 | 7.103E-05 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP3A4 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.523E-05 | 9.792E-05 | AKT1; PIK3R1; TP53; MET; IGF1R |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.631E-05 | 1.012E-04 | GSK3B; SRC; AKT1; PIK3R1; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.056E-05 | 2.028E-04 | ADORA2A; SRC; KDR; AKT1; PIK3R1; MET; IGF1R |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.036E-05 | 1.626E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 6.439E-05 | 2.972E-04 | PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.745E-05 | 1.047E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.869E-05 | 1.990E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.356E-05 | 3.581E-04 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.932E-05 | 2.810E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 7.597E-05 | 3.419E-04 | SRC; MMP2; AKT1; PIK3R1; MMP9 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.252E-04 | 5.007E-04 | MMP3; AKT1; PIK3R1; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.199E-04 | 4.905E-04 | GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.477E-04 | 8.743E-04 | CAMK2B; ADORA2A; ADORA1; AKT1; PIK3R1; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.906E-04 | 9.761E-04 | POLB; SRC; CDK1; PIK3R1; TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.637E-04 | 9.127E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.373E-04 | 1.047E-03 | ABCC1; PIM1; CYP1B1; TP53; MMP9; MET; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.846E-04 | 1.168E-03 | LMNA; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.037E-04 | 9.761E-04 | GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.079E-04 | 4.518E-04 | ALK; AKT1; PIK3R1; TP53 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 9.743E-04 | 2.784E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 8.062E-05 | 3.539E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.048E-04 | 7.523E-04 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.833E-05 | 1.594E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.607E-04 | 6.286E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 9.225E-04 | 2.678E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.048E-04 | 7.523E-04 | AKT1; PIK3R1; MET; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.021E-04 | 9.761E-04 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 9.225E-04 | 2.678E-03 | CDK1; AKT1; PIK3R1; IGF1R |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.021E-04 | 9.761E-04 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.299E-04 | 8.276E-04 | CXCR1; SRC; MET; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.151E-03 | 3.237E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.833E-03 | 5.000E-03 | ALOX5; AKT1; PIK3R1; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 2.133E-03 | 5.647E-03 | CAMK2B; AR; CDK1; IGF1R |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.833E-03 | 5.000E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 4.958E-05 | 2.412E-04 | CDA; TK1; CYP3A4; XDH |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 5.736E-03 | 1.324E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 3.582E-03 | 8.831E-03 | GSK3B; AKT1; PIK3R1; IGF1R |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.318E-03 | 8.412E-03 | GSK3B; AKT1; PIK3R1; PYGL |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.582E-03 | 8.831E-03 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 4.456E-03 | 1.070E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.229E-03 | 1.222E-02 | PIM1; AKT1; STAT6; PIK3R1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.183E-04 | 1.005E-03 | CSNK2A1; SRC; MET; IGF1R |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 7.467E-03 | 1.680E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 6.348E-03 | 1.446E-02 | ADORA3; ADORA1; AKT1; PIK3R1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 3.894E-04 | 1.168E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 7.918E-03 | 1.738E-02 | CAMK2B; SRC; AKT1; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 9.040E-03 | 1.960E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 9.791E-03 | 2.073E-02 | CAMK2B; GSK3B; TYR |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 7.567E-03 | 1.682E-02 | CAMK2B; SRC; MMP2 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.669E-02 | 3.210E-02 | SRC; AKT1; PIK3R1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 9.791E-03 | 2.073E-02 | PIK3R1; NFKB1; PTK2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.006E-02 | 2.081E-02 | AKT1; PIK3R1; HIF1A |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.298E-02 | 2.567E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.006E-02 | 2.081E-02 | CAMK2B; AKT1; PYGL |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.146E-02 | 2.293E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.742E-02 | 3.266E-02 | AKT1; PIK3R1; IGF1R |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.089E-02 | 2.202E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.759E-02 | 4.776E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 2.348E-02 | 4.184E-02 | CSNK2A1; SRC; AKT1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.572E-02 | 4.495E-02 | CXCR1; AKT1; PIK3R1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.053E-02 | 3.732E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.093E-02 | 3.768E-02 | AKT1; PIK3R1; IGF1R |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.742E-02 | 3.266E-02 | GSK3B; CDK1; TP53 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.855E-02 | 3.442E-02 | GSK3B; MET; PTK2 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 2.826E-03 | 7.266E-03 | AKT1; PIK3R1; IGF1R |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.350E-03 | 6.131E-03 | AKT1; PIK3R1; HIF1A |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.791E-03 | 9.222E-03 | CA2; CYP3A4; ABCG2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.928E-03 | 5.180E-03 | ADORA1; AKT1; PIK3R1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.444E-02 | 4.314E-02 | GSK3B; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.969E-02 | 3.616E-02 | MAOA; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.676E-02 | 3.210E-02 | AKT1; PIK3R1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.606E-02 | 3.143E-02 | ABCC1; ABCG2 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.036E-02 | 2.120E-02 | MAOA; TYR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.560E-03 | 1.080E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.898E-04 | 7.268E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1 |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1; SRC |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CA9; FLT3; FLT3; IGF1R; CYP19A1; CDK1; KDR; KDR; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; MMP3; TYR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; ADORA2A |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| NA: NA | HIV infections | NA | AHR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TK1; FLT3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; HIF1A |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; ADK |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; KDR; KDR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; ADORA2A; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TK1; FLT3; FLT3; AURKB; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; ADORA2A; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ADORA2A; ADORA1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TK1; FLT3; MMP2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; ADK; IGF1R; ADORA2A; CDK1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2 |
| A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; CYP3A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; KDR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADORA2A |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; CA9; AKT1; MET; TK1; CSNK2A1; FLT3; FLT3; MMP2; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MMP9; NFKB1; PIM1; TP53; CA1; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; TK1; CDA; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MMP9; TP53; KDR; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ADORA3; ADORA2A; ADORA1; CA1; CA1 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; ADORA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |